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Background—The safety and efficacy of drug-eluting stents (DES) among more generalized “real-world” patients than
those enrolled in pivotal randomized controlled trials (RCTs) are controversial. We sought to perform a meta-analysis
of DES studies to estimate the relative impact of DES versus bare metal stents (BMS) on safety and efficacy end points,
particularly for non–Food and Drug Administration–labeled indications.
Methods and Results—Comparative DES versus BMS studies published or presented through February 2008 with 100
total patients and reporting mortality data with cumulative follow-up of 1 year were identified. Data were abstracted
from studies comparing DES with BMS; original source data were used when available. Data from 9470 patients in 22
RCTs and from 182 901 patients in 34 observational studies were included. RCT and observational data were analyzed
separately. In RCTs, DES (compared with BMS) were associated with no detectable differences in overall mortality
(hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.81 to 1.15; P0.72) or myocardial infarction (HR, 0.95; 95%
CI, 0.79 to 1.13; P0.54), with a significant 55% reduction in target vessel revascularization (HR, 0.45; 95% CI, 0.37
to 0.54; P0.0001); point estimates were slightly lower in off-label compared with on-label analyses. In observational
studies, DES were associated with significant reductions in mortality (HR, 0.78; 95% CI, 0.71 to 0.86), myocardial
infarction (HR, 0.87; 95% CI, 0.78 to 0.97), and target vessel revascularization (HR, 0.54; 95% CI, 0.48 to 0.61)
compared with BMS.
Conclusions—In RCTs, no significant differences were observed in the long-term rates of death or myocardial infarction
after DES or BMS use for either off-label or on-label indications. In real-world nonrandomized observational studies
with greater numbers of patients but the admitted potential for selection bias and residual confounding, DES use was
associated with reduced death and myocardial infarction. Both RCTs and observational studies demonstrated marked
and comparable reductions in target vessel revascularization with DES compared with BMS. These data in aggregate
suggest that DES are safe and efficacious in both on-label and off-label use but highlight differences between RCT and
observational data comparing DES and BMS. (Circulation. 2009;119:3198-3206.)
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Drug-eluting stents (DES) are currently implanted in themajority of the 2 million patients undergoing percu-
taneous coronary intervention each year. The evidence base
for initial DES approvals by the US Food and Drug Admin-
istration (FDA) has consisted largely of randomized con-
trolled trials (RCTs) enrolling patients with mostly stable
coronary artery disease and relatively noncomplex, single, de
novo coronary artery lesions. Data from these RCTs have
suggested that overall rates of death and myocardial infarc-
tion (MI) are similar among DES- and bare metal stent
(BMS)–treated patients,1–3 perhaps because of the offsetting
risks/benefits of DES.4,5 Yet, DES are currently being used
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“off label” in higher-risk patients and in more complex
lesions in 60% to 70% of cases,6,7 and concerns have arisen
about the appropriateness of the routine use of DES in the
“real world.”
Clinical Perspective on p 3206
These concerns have been based primarily on 2 factors: the
observation of higher stent thrombosis rates when DES are
used in more unrestricted patient populations than in the
carefully controlled approval RCTs2,8 and the hypothesis that
DES efficacy may be mitigated outside the carefully selected
clinical trial population of approval RCTs. Although ade-
quately powered RCTs designed to address these issues
comprehensively in off-label patient and lesion subsets have
not been completed, modest-sized RCTs and numerous large-
scale observational analyses examining real-world use of
DES have been conducted. To date, there has been no
systematic attempt to synthesize the current data on DES
off-label and real-world DES use. We therefore performed a
systematic review and meta-analysis to examine the relative
safety and effectiveness of DES compared with BMS across
a broad spectrum of patients.
Methods
Study Objectives and Criteria for
Inclusion/Exclusion
Studies eligible for inclusion included those published or presented
at a major cardiovascular meeting through February 2008 in which
100 patients were enrolled comparing either the commercially
available versions of the CYPHER (Cordis, Miami Lakes, Fla) or
TAXUS (Boston Scientific, Natick, Mass) DES with BMS and in
which mortality data with follow-up1 year from stent implantation
were available. Landmark data, or analyses that censored patients at
a specified time point after stent implantation, were not included
unless presented cumulatively. For example, the Basel Kosten
Effektivitats Trial (BASKET) study was included that used all
cumulative data rather than landmarked data presented as BASKET–
Late Thrombotic Events (BASKET-LATE); the Global Registry of
Acute Coronary Events (GRACE) registry data presented at the
European Society of Cardiology World Congress 2007 were ex-
cluded because in-hospital events were censored. Also excluded
were studies that did not report outcomes data at a fixed time point
(and with the same follow-up duration for both stent types), studies
using a control group from another study already in the meta-anal-
ysis, and studies that were themselves meta-analyses.
Data Search and Acquisition
We searched several sources for published/presented studies, includ-
ing MEDLINE, the Cochrane database, www.clinicaltrials.gov,
www.clinicaltrialresults.org, www.tctmd.com, www.cardiosource.com,
EuroIntervention journal, and abstracts/presentations from major car-
diovascular meetings. The search string broadly included “stent and
(-eluting or sirolimus or paclitaxel)” with slight modifications based
on the source. Studies were identified in 2 independent searches
(performed by A.G. and S.I.) with conflicts adjudicated by a third
reviewer (A.J.K.).
Because of the varying lengths of follow-up and varying baseline
risk among included studies, the measure of association derived was
a relative risk rather than absolute risk or event rate. As a result,
studies with zero events in either the BMS or DES arm for a given
end point were abstracted but were not used in the analyses (total of
2 studies). Hazard ratios (HRs) or relative risks with confidence
intervals (CIs) were either directly abstracted or derived on the basis
of the ratio of reported event rates. The most updated or most
inclusive data for a given study were chosen for abstraction.
Study End Points
The primary end points chosen for this analysis were all-cause death,
MI, and target vessel revascularization (TVR). Studies reporting only
cardiac death were abstracted but are not reported in analyses of
all-cause death. Two studies reporting only Q-wave MI (Washington
Hospital Center, RESTEM) were included in the analyses of MI.
Studies reporting only target lesion revascularization but not TVR
data were not included in primary TVR analyses.
Analyses of RCTs and Observational Studies
We prespecified separate analyses of RCTs and observational studies
given the inherent differences between these types of study designs.9
For RCTs, all studies meeting inclusion/exclusion criteria were
included in the primary analysis. Additional prespecified stratified
analyses of trials according to US FDA labeling (instructions for use)
were conducted. Trials confined to MI patients or involving nonap-
proved indications (eg, chronic total occlusions, bifurcation lesions,
or other complex lesions) were classified as off-label uses. Addi-
tional sensitivity analyses confined to RCTs with follow-up extend-
ing to 2, 3, and 4 years were prespecified.
For observational studies (defined as nonrandomized comparisons
of DES versus BMS, including nonrandomized comparisons within
an RCT investigating other therapies), all studies meeting inclusion/
exclusion criteria were included in the primary meta-analysis.
However, given the a priori heterogeneous nature of observational
analyses, separate subanalyses were prespecified. An analysis con-
fined to large observational studies (1000 total patients) was
conducted. Separate analyses using unadjusted estimates and ad-
justed estimates were assessed. Additionally, estimates derived from
studies using propensity score matching were considered within a
separate substratum. An individual included study could be used in
several categories (eg, if unadjusted, adjusted, and propensity-
matched data were reported); however, the highest-quality estimate
was picked for the overall meta-analysis (using the following rank
order: propensity matchedadjustedunadjusted). Additional sensi-
tivity analyses confined to observational studies with follow-up
extending to 2 and 3 years were prespecified. Finally, analyses
were performed stratified by the type of enrollment: sequential
(consecutive time periods of BMS followed by DES use) or
concurrent (simultaneous BMS and DES use).
Meta-Analyses
Meta-analyses were based on cumulative data from the time of stent
implantation. A single time point estimate for each study end point
was chosen for the analysis, assuming a constant hazard of DES
versus BMS throughout the follow-up period. Both fixed-effects
(inverse-variance weighted) and random-effects (DerSimonian and
Laird) models are reported.10,11 Statistical heterogeneity was assessed
with Cochran Q via a 2 test and was quantified with the I2 test.12
Figure 1. Search strategy and included/excluded studies.
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The influence of individual studies was examined by excluding
studies 1 at a time, and testing for systematic bias was performed
using funnel plots and the Begg test.13 Exploratory bivariate meta-
regressions were performed to assess heterogeneous study effects
and included regressions of the log-HR on the total number of
patients within a study, total number of DES patients, percentage of
diabetic patients, and percentage of patients undergoing protocol-
mandated angiographic follow-up. All analyses were performed with
Stata 10.0 (Stata Corp, College Station, Tex).
Results
A total of 22 RCTs that enrolled 9470 patients and 34
observational studies reporting data from 182 901 patients
met the study criteria and were included in the comprehensive
meta-analysis. A flow diagram depicting the overall search
strategy is demonstrated in Figure 1, and characteristics of the
included studies are shown in the Appendix of the online-
Figure 2. Meta-analysis of all-cause mortality with DES vs BMS. A, RCTs; B, observational studies. Dots represent the individual study
estimates; boxes, study weights; and lines, 95% CIs.
3200 Circulation June 30, 2009






only Data Supplement. Among the RCTs, 10 trials (4818
patients) enrolled patients with lesions consistent with the
FDA-approved indications for DES use, whereas 12 trials (4049
patients) enrolled off-label patients (including 7 trials of DES
versus BMS in acute MI). Among the observational studies, 19
studies (136 558 patients) used statistical designs (matching,
covariate adjustment, or propensity-based adjustment) to adjust
for differences between the DES and BMS patients.
Mortality
In 21 RCTs, the mortality HR for DES versus BMS was 0.97
(95% CI, 0.81 to 1.15; P0.72) in both fixed-effects and
random-effects models with no observed heterogeneity (Figure
2A). Mortality also was not significantly different between
DES- and BMS-treated patients in analyses restricted to
studies including follow-up extending to 2, 3, and 4
years (Table 1). Among trials examining off-label use of
DES, the HR was 0.84 (95% CI, 0.62 to 1.13; P0.24).
In 31 observational studies, DES versus BMS use was
associated with a 22% reduction in mortality (HR, 0.78; 95%
CI, 0.71 to 0.86; P0.001) in a random-effects model and an
18% reduction in mortality (0.82; 95% CI, 0.78 to 0.85) in a
fixed-effects model (Figure 2B). There was a high level of
heterogeneity (I271%; P0.001). However, the relative
benefit of DES versus BMS was consistent among large
observational analyses (those enrolling 1000 patients),
among studies reporting follow-up extending to 2 and 3
years, and among studies reporting adjusted data (Table 1).
There was no apparent systematic bias as assessed by
funnel plots among either the RCTs or observational studies
(Begg test, P0.79 and 0.71, respectively). No individual
study unduly influenced the primary effects estimate, and
meta-regressions conducted to investigate the heterogeneity
in studies demonstrated no variability in the HR based on
number of enrolled patients, number of DES patients, or
percentage of diabetic patients.
Myocardial Infarction
In 20 RCTs, the HR for DES versus BMS was 0.95 (95% CI,
0.79 to 1.13; P0.54) in the fixed-effects model with
minimal heterogeneity (I23.0%; P0.42; Figure 3A). The
hazard of MI was similar in analyses restricted to studies
including follow-up extending to 2, 3, and 4 years
(Table 2). Among trials of off-label use, the HR was 0.77
(95% CI, 0.54 to 1.10; P0.19).
In 25 observational studies, DES versus BMS use was
associated with a 13% reduction in MI (HR, 0.87; 95% CI,
0.78 to 0.97; P0.014 in a random-effects model; Figure
3B). There was again a high level of heterogeneity
(I260.3%; P0.001). However, the relative benefit of DES
versus BMS was consistent among large observational anal-
yses (those enrolling 1000 patients), as well as among
studies reporting follow-up extending to 2 and 3 years,
but was somewhat attenuated when restricted to observational
studies reporting adjusted data (HR, 0.91; 95% CI, 0.81 to
1.01; P0.08; Table 2).
A trend was present that was suggestive of systematic bias
as assessed by funnel plots favoring DES in the RCTs but not
in the observational studies with respect to the MI end point
(Begg test, P0.052 and P0.12, respectively). No individ-
ual randomized or observational study unduly influenced the
primary effects estimate, and meta-regressions demonstrated
no variability in the HR based on number of enrolled patients,
number of DES patients, or percentage of diabetic patients.
Target Vessel Revascularization
In 16 RCTs, DES versus BMS resulted in a 55% reduction in
TVR (HR, 0.45; 95% CI, 0.37 to 0.54; P0.001) in the
Table 1. All-Cause Mortality in RCTs and Observational Studies
Studies, n Patients, n Median Follow-Up, y Random Effects Fixed Effects P I2, % Heterogeneity P
RCTs
Overall 21 8867 2.9 0.97 (0.81–1.15) 0.97 (0.81–1.15) 0.72 0 0.92
Trials with 2 y of follow-up 11 5273 4.2 0.99 (0.81–1.21) 0.99 (0.81–1.21) 0.89 0 0.80
Trials with 3 y of follow-up 8 4684 4.4 1.00 (0.80–1.23) 1.00 (0.80–1.23) 0.97 0 0.81
Trials with 4 y of follow-up 6 3328 5.0 1.01 (0.80–1.29) 1.01 (0.80–1.29) 0.91 0 0.70
On-label trials 10 4818 4.0 1.05 (0.84–1.30) 1.05 (0.84–1.30) 0.69 0 0.93
Off-label trials 12 4049 1.5 0.84 (0.62–1.13) 0.84 (0.62–1.13) 0.24 0 0.80
Observational studies
Overall 31 169 595 2.5 0.78 (0.71–0.86) 0.81 (0.78–0.85) 0.01 71 0.01
Studies with 1000 patients 22 166 386 2.6 0.77 (0.69–0.85) 0.81 (0.78–0.85) 0.01 78 0.01
Studies with 2 y of follow-up 18 143 217 2.8 0.77 (0.69–0.85) 0.82 (0.78–0.85) 0.01 78 0.01
Studies with 3 y of follow-up 8 76 298 3.5 0.79 (0.67–0.95) 0.87 (0.82–0.93) 0.01 83 0.01
Studies with 4 y of follow-up 2 39 799 4.0 1.01 (0.94–1.10) 1.01 (0.94–1.10) 0.73 0 0.57
Unadjusted analyses 24 129 328 2.1 0.70 (0.63–0.77) 0.68 (0.66–0.71) 0.01 74 0.01
Adjusted analyses 19 136 558 2.7 0.79 (0.71–0.89) 0.82 (0.79–0.86) 0.01 76 0.01
Propensity-matched analyses 6 34 350 2.2 0.82 (0.71–0.95) 0.80 (0.74–0.87) 0.01 56 0.04
Sequential enrollment 14 41 237 2.2 0.88 (0.76–1.01) 0.88 (0.81–0.95) 0.07 45 0.03
Concurrent enrollment 13 116 612 2.7 0.71 (0.62–0.83) 0.80 (0.76–0.84) 0.01 83 0.01
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random-effects model with a high level of heterogeneity
(I253.2%; P0.006; Figure 4A). The benefit of DES versus
BMS with respect to TVR was similar in analyses restricted
to studies including follow-up extending to 2, 3, and 4
years with less heterogeneity, particularly among the last
group (Table 3). Randomization to DES versus BMS reduced
TVR by 62% in trials examining off-label DES use (HR,
0.38; 95% CI, 0.27 to 0.52; P0.001).
In 18 observational studies, use of DES compared with
BMS reduced TVR by 46% (HR, 0.54; 95% CI, 0.48 to 0.61;
P0.001) in a random-effects model (Figure 4B). There was
again a high level of heterogeneity (I269.7%; P0.001).
However, the relative benefit of DES versus BMS was
consistent with the aggregate analysis among large observa-
tional studies (those enrolling 1000 patients), studies re-
porting follow-up extending to 2 and 3 years, unadjusted
studies, and studies reporting adjusted data, including
propensity-matched registries and multivariable-adjusted reg-
istries (Table 3).
There was no evident systematic bias assessed by funnel
plots evident in either the RCTs or observational studies with
respect to the TVR end point (Begg test, P0.56 and
P0.11, respectively). Meta-regressions performed in the
RCTs demonstrated a consistent HR of TVR reduction with
Figure 3. Meta-analysis of MI with DES
vs BMS. A, RCTs; B, observational stud-
ies. Dots represent the individual study
estimates; boxes, study weights; and
lines, 95% CIs.
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DES regardless of the percentage of patients undergoing
protocol-mandated routine angiographic follow-up in the
RCTs (P0.73; Figure 5). However, there did appear to be a
greater relative benefit of DES in smaller studies (P0.02 for
meta-regression of HR on total number of enrolled patients).
No individual RCT or observational study unduly influenced the
primary effects estimate, and meta-regressions among the ob-
servational studies conducted demonstrated no variability in the
HR based on number of enrolled patients, number of DES
patients, or percentage of diabetic patients within a study.
Discussion
The primary findings from this systematic review and meta-
analysis of DES versus BMS studies are the following. First,
in RCTs, treatment with DES compared with BMS was
associated with no detectable differences in death or MI in
either off-label or on-label studies and was associated with a
significant 55% reduction in TVR. Second, in observational
studies, the nonrandomized use of DES versus BMS was
associated with significant 22% and 13% reductions in
all-cause mortality and MI, respectively, and a significant
46% reduction in TVR, although a high level of heterogeneity
was present among these studies. The observed differences
between the findings within RCTs and observational analyses
demonstrate that reliance on neither should be absolute, but
the collective data appear consistent in demonstrating at a
minimum the absence of a significant safety hazard of DES
compared with BMS while confirming the presence of
significant DES efficacy across a broad range of lesions and
patients at various risk.
Evidence of DES safety and efficacy is derived from 2
types of complementary studies: RCTs, which are typically
small to modest sized and not powered to assess hard safety
end points such as death or MI, and large-scale observational
studies, in which the results of the nonrandomized selection
of DES versus BMS have been compared in routine clinical
practice. These 2 different types of study designs have
strengths and limitations that affect the clinical context and
interpretation of their results. Although RCT data, by mini-
mizing the influence of both measured and unmeasured
confounders, represent the purest comparison between 2
treatment strategies and can minimize treatment selection
bias, observational studies may be more generalizable and
less subject to enrollment bias. Thus, both types of data are
useful in assessing the relative safety and efficacy of DES
compared with BMS.
There may be several possible explanations why the rates
of death and MI were found to be significantly reduced with
the use of DES compared with BMS in the observational
studies with an attenuated effect in the RCTs. Proponents of
observational data cite their added generalizability and the
fact that nearly 20 times more patients have been studied in
the observational registries as in the RCTs, providing much
more power to detect differences in low-frequency safety
events. Conversely, observational analyses are subject to
confounding with respect to the nonrandomized choice of
either DES or BMS. Multivariable adjustment and/or propen-
sity matching can be used to mitigate the effect of measured
confounders on the DES versus BMS effect estimate within
individual studies. As such, the observed attenuation of the
overall summary estimate of mortality and MI favoring DES
compared with BMS in the adjusted compared with the
unadjusted analyses is notable.
Nonetheless, conventional statistical approaches used in
observational analyses have limited ability to address the
influence of unmeasured confounders on the overall effect
estimate. For example, the decision to use DES may be based
on unmeasured patient characteristics and may importantly
Table 2. MI in RCTs and Observational Studies
Studies, n Patients, n Median Follow-Up, y Random Effects Fixed Effects P I2, % Heterogeneity P
RCTs
Overall 20 8850 2.9 0.94 (0.78–1.13) 0.95 (0.79–1.13) 0.54 3 0.42
Trials with 2 y of follow-up 11 5273 4.1 0.96 (0.74–1.25) 0.99 (0.81–1.23) 0.76 25 0.20
Trials with 3 y of follow-up 8 4684 4.4 1.08 (0.86–1.34) 1.08 (0.86–1.34) 0.52 0 0.61
Trials with 4 y of follow-up 6 3328 5.0 1.04 (0.80–1.34) 1.04 (0.80–1.34) 0.79 0 0.46
On-label trials 9 4318 4.4 1.03 (0.81–1.30) 1.03 (0.81–1.30) 0.82 0 0.76
Off-label trials 12 4532 1.5 0.77 (0.54–1.10) 0.83 (0.62–1.10) 0.19 26 0.19
Observational studies
Overall 25 130 191 2.5 0.87 (0.78–0.97) 0.95 (0.91–1.00) 0.01 60 0.01
Analyses with 1000 patients 16 126 931 2.6 0.90 (0.81–0.99) 0.96 (0.91–1.01) 0.03 63 0.01
Analyses with 2 y of follow-up 12 103 663 2.9 0.93 (0.83–1.05) 0.97 (0.91–1.02) 0.23 64 0.01
Analyses with 3 y of follow-up 5 58 255 3.6 0.88 (0.70–1.11) 0.97 (0.89–1.05) 0.28 68 0.02
Analyses with 4 y of follow-up 1 35 262 4.0 1.01 (0.91–1.11) 1.01 (0.91–1.11) 0.84 NA NA
Unadjusted analyses 19 88 457 2.0 0.81 (0.69–0.96) 0.88 (0.83–0.93) 0.01 78 0.01
Adjusted analyses 14 107 294 2.8 0.91 (0.81–1.01) 0.96 (0.91–1.01) 0.08 61 0.01
Propensity-matched analyses 4 22 830 2.0 0.94 (0.79–1.12) 0.95 (0.87–1.03) 0.48 61 0.05
Sequential enrollment 10 20 108 2.0 0.69 (0.55–0.87) 0.70 (0.60–0.82) 0.01 43 0.07
Concurrent enrollment 11 98 337 2.7 0.98 (0.87–1.11) 1.01 (0.95–1.08) 0.73 60 0.01
Kirtane et al Meta-Analysis of Drug-Eluting Stents 3203






affect subsequent treatment decisions, including medication
use. The longer duration of dual antiplatelet therapy required
with DES2,3 may reduce long-term adverse event rates inde-
pendently of stent selection.14 Thus, it is likely that at least
some of the differences observed in the relative safety of
DES versus BMS between the observational studies and
the RCTs represent the effect of residual (or unmeasured)
confounding.
These limitations notwithstanding, the observed point es-
timates for both death and MI with DES compared with BMS
were less than unity in both the RCTs and the observational
studies, suggesting that DES are safe across a broad cross
Figure 4. Meta-analysis of TVR with DES vs BMS. A, RCTs; B, observational studies. Dots represent the individual study estimates;
boxes, study weights; and lines, 95% CIs.
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section of patients and lesions with coronary artery disease.
Prior analyses of on-label DES use have demonstrated an
“offsetting risk” of restenosis and stent thrombosis over
longer-term follow-up, with an increased rate of restenosis-
related events among BMS-treated patients balanced against
an increased rate of primary thrombosis-related events among
DES-treated patients.4,5,15 The absolute benefits of DES
compared with BMS in more unselected (and higher resteno-
sis risk) patients may be greater. Whether the relative and
absolute risks of stent thrombosis are also concomitantly
higher with DES versus BMS in such patients is unknown,
but it is clear that late thrombotic events also occur with
unselected use of BMS.16
With respect to the efficacy of DES, the results of both
RCT studies and observational analyses were concordant in
demonstrating a marked reduction in recurrent ischemia
necessitating repeat TVR. This effect was similar in magni-
tude between the RCT studies and observational analyses and
in the RCTs was independent of the percentage of routine
angiographic follow-up performed. The consistency and mag-
nitude of the reduction in TVR with DES are notable,
particularly given concerns that high levels of routine angio-
graphic follow-up and a lack of lesion complexity may have
overestimated the efficacy of DES in pivotal randomized
trials. Among RCTs, the reduction in TVR, death, and MI
with DES compared with BMS tended to be greater in
off-label compared with on-label studies, supporting the data
from the observational studies that DES are likely safe and
effective in an unrestricted real-world population.
As with any systematic review and meta-analysis, the
conclusions drawn from such data are subject to the limita-
tions of the original included studies themselves. Although
strict criteria were used, the included studies represent a
comprehensive attempt to cull together published and unpub-
lished literature in this area, and as such, summary-level
estimates of individual study effects were used. Finally,
heterogeneity was present among the observational studies
included in this meta-analysis. Attempts to investigate
sources of heterogeneity through various sensitivity analyses
and meta-regression did not reveal a simple explanation or
way to account for this variability, and the overall magnitude
and directionality of the summary DES versus BMS estimates
appeared consistent in these subanalyses. Even if one were to
consider the degree of heterogeneity to be so significant so as
to preclude quantitative assessment of a summary estimate,
from this systematic review, it appears that the preponderance
of the evidence does not suggest an adverse safety signal with
DES compared with BMS.
Conclusions
The use of DES compared with BMS does not appear to be
associated with adverse safety outcomes such as death or MI
when used either off label in RCTs or in an unrestricted
fashion as selected in the nonrandomized observational stud-
ies and was associated with a significant and comparable
Table 3. TVR in RCTs and Observational Studies
Studies, n Patients, n Median Follow-Up, y Random Effects Fixed Effects P I2, % Heterogeneity P
RCTs
Overall 16 7291 3.2 0.45 (0.37–0.54) 0.51 (0.45–0.57) 0.01 53 0.01
Trials with 2 y of follow-up 9 4859 4.3 0.51 (0.42–0.63) 0.55 (0.49–0.63) 0.01 50 0.05
Trials with 3 y of follow-up 8 4684 4.4 0.53 (0.43–0.65) 0.56 (0.49–0.64) 0.01 51 0.05
Trials with 4 y of follow-up 6 3328 5.0 0.51 (0.44–0.59) 0.51 (0.44–0.59) 0.01 0 0.47
On-label trials 9 4618 4.2 0.53 (0.43–0.65) 0.54 (0.48–0.62) 0.01 49 0.05
Off-label trials 8 2673 1.6 0.38 (0.27–0.52) 0.42 (0.34–0.52) 0.01 48 0.06
Observational studies
Overall 18 74 154 2.2 0.54 (0.48–0.61) 0.57 (0.54–0.60) 0.01 70 0.01
Analyses with 1000 patients 11 71 952 2.2 0.55 (0.48–0.63) 0.58 (0.55–0.61) 0.01 80 0.01
Analyses with 2 y of follow-up 10 62 397 2.4 0.57 (0.50–0.64) 0.58 (0.55–0.62) 0.01 73 0.01
Analyses with 3 y of follow-up 3 21 786 3.0 0.50 (0.31–0.82) 0.60 (0.53–0.67) 0.01 90 0.01
Unadjusted analyses 13 55 866 2.2 0.60 (0.49–0.75) 0.73 (0.69–0.77) 0.01 88 0.01
Adjusted analyses 11 63 456 2.2 0.54 (0.46–0.63) 0.58 (0.54–0.61) 0.01 79 0.01
Propensity-matched analyses 4 21 914 1.5 0.63 (0.48–0.82) 0.60 (0.53–0.65) 0.01 90 0.01
Sequential enrollment 7 25 962 2.2 0.52 (0.42–0.63) 0.53 (0.49–0.58) 0.01 67 0.01
Concurrent enrollment 9 47 879 2.2 0.56 (0.47–0.66) 0.61 (0.57–0.66) 0.01 72 0.01
Figure 5. Meta-regression of hazard of TVR on percentage of
angiographic follow-up in RCTs. The size of the circles repre-
sents the individual study weights.
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reduction in TVR in both types of studies. Large-scale RCTs
are required to ascertain the true effects of DES compared
with BMS with respect to rates of death and MI. However, in
the absence of definitive large-scale randomized data directly
comparing DES to BMS in unselected patients, these find-
ings, derived from 190 000 total patients treated in 56
studies, suggest that DES are safe for both on-label and
off-label use and have comparable efficacy in both RCTs and
in the real world.
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CLINICAL PERSPECTIVE
Drug-eluting stents (DES) are currently implanted in the majority of the 2 million patients undergoing percutaneous
coronary intervention each year. The evidence base for initial DES approvals by the US Food and Drug Administration has
consisted largely of randomized controlled trials enrolling patients with relatively noncomplex lesions. Data from these
trials have suggested that rates of death and myocardial infarction are similar among DES- and bare metal stent–treated
patients. Yet, DES are currently being used “off label” in the majority of cases, and concerns have arisen about the
appropriateness of the use of DES in the “real world.” Here, we sought to address DES safety and efficacy by synthesizing
studies of the commercially available formulations of the 2 originally approved DES. A statistical methodology known as
meta-analysis was used to quantitatively combine these studies. Given the inherent differences between randomized
controlled trials and observational studies, each type of study was analyzed separately. In randomized controlled trials, no
significant differences were observed in the long-term rates of either death or myocardial infarction after DES or bare metal
stent use for both off-label and on-label indications. In nonrandomized observational studies, DES use was associated with
reduced death and myocardial infarction. Both randomized controlled trials and observational studies demonstrated marked
and comparable reductions in repeat revascularization with DES compared with bare metal stents. In aggregate, the
unrestricted use of DES compared with bare metal stents did not appear to be associated with adverse safety outcomes and
was associated with a significant reduction in repeat revascularization of the treated vessel.
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Supplemental Table 1:  Randomized Controlled Trials 
 
Name of Study First Author BMS pts DES pts Assessed Outcomes On/Off label Comments Citation 
SCORPIUS D Baumgart 102 98 Death, MI On Diabetic patients with simple lesions 
1 
SESAMI M Menichelli 160 160 Death, MI, TVR Off STEMI 2 
SES SMART A Menozzi 127 127 Death, MI Off Small vessels 3 
TYPHOON C Spaulding 357 355 Death, MI, TVR Off STEMI 4 
PASSION GJ Laarman 309 310 Death, MI Off STEMI 5 
BASKET C Kaiser 281 545 Death*, MI, TVR Off 
Cost effectiveness trial; 
Overall Death data 
abstracted from Kastrati 
Meta-analysis (SES only) 
6, 7 
STRATEGY M Valgimigli 88 87 Death, MI, TVR Off STEMI 8 
Seville L Díaz de la Llera 60 60 Death, TVR Off STEMI 9 
HAAMU-STENT I Tierala 82 82 Death, MI, TVR Off STEMI 10 
MISSION! B van der Hoeven 152 158 Death, MI, TVR Off STEMI 11 
PRISON II M Suttorp  100 100 Death, MI, TVR Off Chronic total occlusions 12 
Pache et al J Pache 250 250 Death, TVR On Open enrollment 13 
Ortolani et al P Ortolani 52 52 Death, MI, TVR On Low ejection fraction 14 
DIABETES P  Jiménez-Quevedo 80 80 Death, MI Off Diabetic patients 15 
SCANDSTENT S Helqvist 159 163 MI, TVR Off Complex disease; Only Cardiac Death reported 
16 
RAVEL* MC Morice 118 120 Death, MI, TVR Off Initial angiographic trial 17 
SIRIUS* J Moses 533 525 Death, MI, TVR On Pivotal Approval trial 18 
C-SIRIUS* E Schampaert 50 50 Death, MI, TVR On Canadian Pivotal trial 19 
E-SIRIUS* J Schofer 177 175 Death, MI, TVR On European Pivotal trial 20 
 
*Original study data obtained from study sponsors. BMS = bare metal stents. DES = drug-eluting stents
TAXUS II* A Colombo 135 131 Death, MI, TVR On Initial angiographic trial 21 
TAXUS IV* G Stone 652 662 Death, MI, TVR On Pivotal Approval trial 22 










Supplemental Table 2:  Observational Studies 
 
Name of Study First Author BMS pts DES pts Measured Outcomes Comments Availability of Adjusted Data Citation 
NHLBI O Marroquin 2110 1312 Death, MI Unselected UA, MV 24 
Metabolic Syndrome R Hoffman 437 297 Death, MI Unselected UA 25 
Ontario J Tu 3751 3751 Death, MI, TVR Unselected PM 26 
Mayo FFR S Lavi 58 58 Death, MI, TVR Unselected UA 27 
Northern New England D Malenka 1013 1011 Death Multivessel disease MV 28 
Harbor AMI A Shah 86 150 MI STEMI; only cardiac death reported UA 
29 
Brazil Large Vessels A Quizhpe 250 250 MI, TVR Large vessels; only cardiac death reported UA 
30 
Italian Diabetic 
Multivessel Disease C Briguori 122 100 Death, MI Diabetics, multivessel
 Matched 31 
McMaster STEMI J Schwalm 137 60 Death, MI, TVR STEMI UA, MV 32 
Rotterdam Off-label J Daemen 1750 2787 Death 
Off-label analyses used 




Center* P Roy 546 546 Death, MI, TVR 
Off-label data used as 
they represent latest 
follow-up 
PM 34 
Asan Medical Center* S Park 3160 4061 Death, MI, TVR Unselected UA,MV, PS 35 
SCAAR S James 21477 13785 Death, MI Unselected MV, PS 36 
Wake Forest* R Applegate 1135 1242 Death, MI, TVR Unselected UA,MV,PS 37 
Western Denmark* L Jensen 8847 3548 Death, MI Unselected UA,MV 38 
New York State E. Hannan 7834 6384 Death, TVR Unselected UA, MV, PM 39 
MIDAS T Vagaonescu 5399 5719 Death MI UA,MV 40 
Massachusetts L Mauri 6210 11516 Death, MI, TVR Unselected UA,PM 41 
STENT* B Brodie 1359 5996 Death, MI, TVR Unselected UA, MV, PS 42 
Liverpool* A Alahmar 2105 913 Death Unselected UA, PM 43 
GHOST * K Harjai 1265 858 Death, MI, TVR Unselected MV 44 
Montevergine E Stabile 1961 2301 TVR Unselected; Only cardiac death reported UA 
45 
DEScover D Williams 397 6509 Death, MI, TVR Unselected UA,MV 46 
Cedars Sinai AMI 
Registry L Kupferwasser 126 128 Death, MI, TVR
 STEMI UA 47 
REAL* A Marzocchi 9565 4550 Death, MI, TVR Unselected UA,MV, PS, PM 
48 
Melbourne P Roy 279 272 Death, MI Unselected UA 49 
Multicenter SVG 
Registry S Ellis 175 175 Death, TVR
 Saphenous Vein Grafts Matched 50 
ACUITY R Mehran 2529 4633 Death, MI Acute Coronary Syndromes UA 
51 
RESTEM L Campolo 3974 807 Death, MI, TVR Unselected UA 52 
ARTS II P Serruys 600 607 Death, MI Multivessel disease UA 53 
ERACI III A Rodriguez 225 225 Death, MI, TVR Multivessel disease UA 54 
Sussex Elderly Behan M 240 95 Death, TVR Elderly patients (unselected) UA 
55 
SMART registry J Choi 2494 3510 Death Unselected UA 56 
 
*Data updated directly from study principal investigators 
BMS = bare metal stents. DES = drug-eluting stents. UA=unadjusted; MV=multivariable analysis; PS=propensity score adjusted; PM=propensity-
matched 
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